TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: LIRA-ADD2SGLT2i - Liraglutide Versus Placebo as add-on to SGLT2 Inhibitors.

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Informed consent obtained before any trial-related activities. Trial-related activities are any procedures that are carried out as part of the trial, including activities to determine suitability for the trial.~* Male or female, age 18 years or older at the time of signing informed consent.~* Diagnosed with type 2 diabetes mellitus.~* HbA1c of 7.0-9.5% (53-80 mmol/mol) (both inclusive).~* Stable dose of an SGLT-2 inhibitor as monotherapy or in combination (including fixed-dose drug combination) with a stable dose of metformin (1500 mg or more, or maximum tolerated dose) for at least 90 days prior to the day of screening. All medications in compliance with current local label.~* Body mass index of 20 kg/m\^2 or above.~Exclusion Criteria:~* Female who is pregnant, breast-feeding or intends to become pregnant or is of child-bearing potential and not using an adequate contraceptive method (adequate contraceptive measure as required by local regulation or practice).~* History of diabetic ketoacidosis while being treated with SGLT2 inhibitors.~* Renal impairment measured as estimated Glomerular Filtration Rate (eGFR) value of less than 60 mL/min/1.73m\^2 as defined by Kidney Disease Improving Global Outcomes (KDIGO) classification using isotope dilution mass spectrometry (IDMS) for serum creatinine measured at screening.~* Treatment with any medication for the indication of diabetes or obesity other than stated in the inclusion criteria within the past 90 days prior to the day of screening. However, short term insulin treatment for a maximum of 14 days during the 90 days prior to screening is allowed.~* Family or personal history of multiple endocrine neoplasia type 2 or medullary thyroid carcinoma. Family is defined as a first degree relative.~* History or presence of pancreatitis (acute or chronic).~* Impaired liver function, defined as ALT 2.5 or more times upper normal limit at screening.~* Subjects presently classified as being in New York Heart Association (NYHA) Class IV.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- liraglutide + SGLT2i ± metformin (Type: EXPERIMENTAL): None
- liraglutide placebo + SGLT2i ± metformin (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Comparison of Treatment for Hoarding Disorder

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Diagnosis of Hoarding Disorder~Exclusion Criteria:~* Individuals with active psychosis, schizophrenia, intellectual disability, or known dementia will be excluded~* Individuals who have participated in either cognitive-behavioral therapy for hoarding (group or individual) or in group Buried in Treasures in the past year

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Group Cognitive-Behavioral Therapy (Type: EXPERIMENTAL): Sixteen sessions of group therapy facilitated by a psychologist.
- Peer Facilitated Support Group (Type: EXPERIMENTAL): Fifteen sessions of peer-facilitated group support.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Comparing Effectiveness of Merocel and Packing With Tranexamic Acid in the Management of Anterior Epistaxis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE4
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Patients with anterior epistaxis older than 18 year and accept to participate in the study~Exclusion Criteria:~* Patients younger than 18 years~* Patients who used anticoagulation therapy~* Patients who have hemodynamically instability~* Traumatic epistaxis~* Patients who have known bleeding disorder

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- Tranexamic acid group (Type: ACTIVE_COMPARATOR): 500mg tranexamic acid is sprayed in the nose by atomizer spray, and then is applied nasal compression by manually.
- Placebo group (Type: PLACEBO_COMPARATOR): 5ml normal saline is sprayed in the nose by atomizer spray, and then is applied nasal compression by manually.
- Merocel Group (Type: ACTIVE_COMPARATOR): Merocel packing is applied.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Safety Study of Sulfonylureas in Neonatal Diabetes Mellitus

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* coding sequence of KCNJ11 or ABCC8 in patients having a permanent neonatal diabetes mellitus~* written informed consent~Exclusion Criteria:~* hypersensibility of sulfonylureas~* severe renal failure (clearance of creatinemia \< 30 ml/min)~* severe hepatic failure (Prothrombin rate \< 70 %)~* Porphyria~* imidazol treatments~* pregnancy~* no social security affiliation

- Gender: ALL
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): Glibenclamide

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Safety and Tolerability Study of UBX1325 in Patients With Diabetic Macular Edema or Neovascular Age-Related Macular Degeneration

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* nAMD patients who, in the opinion of the Investigator, are inadequately responding to or failed current treatment options.~* Active choroidal neovascularization (CNV) associated with age-related macular degeneration as evidenced on FA and SD-OCT at Day 1, including presence of intraretinal or subretinal fluid.~* BCVA in the study eye (most affected) of 70 Early Treatment Diabetic Retinopathy Study (ETDRS) letters or worse at screening and on Day 1.~* Patients who have the capacity to give informed consent and who are willing and able to comply with all study-related procedures and assessments.~Exclusion Criteria:~* Any ocular/intraocular/periocular infection or inflammation in either eye in the past 4 weeks prior to screening.~* Subretinal hemorrhage with bleeding area ≥4 disc area in the study eye~* Concomitant therapy with anti-VEGF therapies (e.g., Avastin®, Lucentis®, or Eylea®) or previous use of these agents in the study eye within approximately 28 days of study enrollment~* Any retinovascular disease or retinal degeneration other than nAMD in the study eye.~* History of systemic and intraocular steroid use for 6 months prior to Day 1. The use of intravitreal nonbiodegradable steroid implants (ex. Iluvien®, Yutiq®, Retisert®) is prohibited.~* Significant media opacities, including cataract, which might interfere with VA, assessment of toxicity, or fundus imaging.~* Any uncontrolled medical condition that, in the opinion of the investigator, would preclude participation in this study.

- Gender: ALL
- Minimum Age: 50 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Treatment with UBX1325 (Type: EXPERIMENTAL): UBX1325, single intravitreal injection, ascending dose

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Safety of Zolpidem-MR Administered Over a Long Term Period as Needed for Insomnia (ZOLONG)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* patients with chronic primary insomnia~The investigator will evaluate whether there are other reasons why a patient may not participate.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 64 Years
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Safety and IOP-Lowering Effects of WB007

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE1/PHASE2
- Number of Arms: 6.0

Eligibility Criteria:
Inclusion Criteria:~* Ocular hypertension or primary open-angle glaucoma in each eye~Exclusion Criteria:~* History of orthostatic hypotension~* Any active ocular disease~* Anticipated wearing of contact lenses during study~* Contraindication to pupil dilatation

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Part 1 (Period 1): WB007 0.05% (Type: EXPERIMENTAL): WB007 0.05%, single dose to study eye on Day 1
- Part 1 (Period 2): WB007 0.15% (Type: EXPERIMENTAL): WB007 0.15%, single dose to study eye on Day 1
- Part 1 (Period 3): WB007 0.4% (Type: EXPERIMENTAL): WB007 0.4%, single dose to study eye on Day 1
- Part 2: WB007 0.15% (Type: EXPERIMENTAL): WB007 0.15%, dosed twice daily for 14 days
- Part 2: WB007 0.4% (Type: EXPERIMENTAL): WB007 0.4%, dosed twice daily for 14 days
- Part 2: Timolol 0.5% (Type: ACTIVE_COMPARATOR): Timolol 0.5%, dosed twice daily for 14 days.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Nasogastric Tube in Premature Babies - Pain and Treatment

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: FACTORIAL
- Observational Model: None
- Primary Purpose: None
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE2
- Number of Arms: 6.0

Eligibility Criteria:
Inclusion Criteria:~* 28 - 32 weeks gestational weeks~* not on mechanical ventilation~Exclusion Criteria:~* high risk group regarding cerebral prognosis

- Gender: ALL
- Minimum Age: 3 Days
- Maximum Age: 8 Weeks
- Healthy Volunteers: t

Study Arms:
- control (Type: NO_INTERVENTION): no fluid, no pacifier
- water (Type: EXPERIMENTAL): water, no pacifier
- sucrose (Type: EXPERIMENTAL): Sucrose, no pacifier
- pacifier (Type: EXPERIMENTAL): No fluid, pacifier
- water and pacifier (Type: EXPERIMENTAL): water, pacifier
- sucrose and pacifier (Type: EXPERIMENTAL): sucrose, pacifier

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Effects of SH T00658ID on Libido

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* OC-associated female sexual dysfunction (FSD) for at least 3 months but no longer than one year and willingness to continue OC use but to switch to SH T00658ID or Microgynon~* Combined score of the sexual desire and arousal domains of the FSFI questionnaire of 18 or below at screening and baseline~Exclusion Criteria:~* Contraindications for oral contraceptive use, for example but not limited to: presence or history of venous or arterial thrombotic / thromboembolic events, hypertension, presence or history of severe hepatic disease

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 50 Years
- Healthy Volunteers: f

Study Arms:
- EV/DNG (Natazia, Qlaira, BAY86-5027, SH T00658ID) (Type: EXPERIMENTAL): Daily oral administration of one capsule BAY86-5027 \[estradiol valerate (EV) / dienogest (DNG)\] for 28 days per cycle in the sequential 4-phasic regimen for 6 treatment cycles.
- EE/LNG (Microgynon) + Placebo (Type: ACTIVE_COMPARATOR): Daily oral administration of one capsule ethinylestradiol (EE) / levonorgestrel (LNG) for 21 days, followed by 1 capsule placebo for 7 days (28 days total per cycle) for 6 treatment cycles.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Comparison of a New Formulation of Insulin Glargine With Lantus in Patients With Type 2 Diabetes on Basal Insulin With Oral Antidiabetic Therapy

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion criteria :~* Participants with type 2 diabetes mellitus~* Substudy inclusion criteria:~  * Completion of the 6-month study period in main study (Visit 10)~ * Randomized and treated with insulin glargine new formulation during the 6- month treatment period (Baseline - Month 6)~Exclusion criteria:~* Age less than (\<) 18 years~* HbA1c \<7.0% or greater than (\>) 10% at screening~* Diabetes other than type 2 diabetes mellitus~* Less than 6 months on basal insulin treatment together with oral antihyperglycemic drug(s) and self-monitoring of blood glucose~* Participants using sulfonylurea in the last 2 months before screening visit~* Any contraindication to use of insulin glargine as defined in the national product label~* Use of insulin pump in the last 6 months before screening~* Initiation of new glucose-lowering medications in the last 3 months before screening visit~* History or presence of significant diabetic retinopathy or macular edema likely to require laser or injectable drugs or surgical treatment during the study period~* Pregnant or breast-feeding women or women who intend to become pregnant during the study period~* Substudy exclusion criteria:~  * Participant not willing to use the adaptable injection intervals on at least two days per week~The above information is not intended to contain all considerations relevant to a participant's potential participation in a clinical trial.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- HOE901-U300 (Type: EXPERIMENTAL): None
- Lantus (Type: ACTIVE_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Clinical Trial of Gabapentin to Decrease Postoperative Delirium and Pain

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Male or female ≥65 years of age undergoing surgery involving the spine, hip or knee replacement.~* English speaking.~* Anticipated to stay in the hospital for at least 48 hours.~Exclusion Criteria:~* Patients who take gabapentin preoperatively, or have known sensitivity to the drug, or those unable to be randomized to receive gabapentin.~* Subjects who are unable to provide informed consent.~* Patients with a history of narcotic tolerance.~* Patients with planned two stage spinal procedures (anterior-posterior spinal fusion to be done on two separate days).

- Gender: ALL
- Minimum Age: 65 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Gabapentin (Type: EXPERIMENTAL): Double blind, placebo controlled
- Placebo (Type: PLACEBO_COMPARATOR): Double blind

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Primary Vaccination Study With GSK Biologicals' Pneumococcal Vaccine in Healthy Infants in Vietnam

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Male or female subjects between, and including 6-12 weeks of age at the time of the first vaccination.~* Subjects for whom the investigator believes that their parents/guardians can and will comply with the requirements of the protocol.~* Written and signed or thumb-printed informed consent obtained from the parent(s)/LAR of the child. Where parent(s)/guardian(s) are illiterate, the consent form will be countersigned by a witness.~* Free of obvious health problems as established by medical history and clinical examination before entering into the study.~Exclusion Criteria:~* Use of any investigational or non-registered product other than the study vaccine(s) within 30 days preceding the first dose of study vaccine, or planned use during the study period.~* Concurrently participating in another clinical study, at any time during the study period, in which the subject has been or will be exposed to an investigational or a non-investigational product.~* Acute disease and/or fever at the time of enrolment.~* History of any reaction or hypersensitivity likely to be exacerbated by any component of the vaccine(s).~* History of chronic condition(s) requiring treatment such as cancer or autoimmune disease.~* Hypersensitivity to latex.~* Previous vaccination against diphtheria, tetanus, pertussis, Hemophilus influenzae type b and/or Streptococcus pneumoniae. Locally recommended EPI vaccines to be given at birth are allowed, but should be administered at least one month before the first dose of the study vaccine is administered. Other locally recommended vaccines are allowed, even if concomitantly administered with the study vaccines, but should be documented in the eCRF.

- Gender: ALL
- Minimum Age: 6 Weeks
- Maximum Age: 12 Weeks
- Healthy Volunteers: t

Study Arms:
- Synflorix Group (Type: EXPERIMENTAL): Subjects receiving Synflorix™(GSK 1024850A) co-administered along with Infanrix hexa™.
- Control Group (Type: ACTIVE_COMPARATOR): Subjects receiving Infanrix hexa™ vaccine alone.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Phase 2 Dose-Response Study Evaluating the Safety and Efficacy of NCX 470 vs Latanoprost in Subjects With Open-Angle Glaucoma or Ocular Hypertension

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Diagnosis of open-angle glaucoma or ocular hypertension in both eyes~* Qualifying IOP at 3 time points throughout the day at 2 visits following washout of IOP-lowering medication, if applicable~* Qualifying best-corrected visual acuity (BCVA) using the Early Treatment of Diabetic Retinopathy Study (ETDRS) protocol in each eye~* Ability to provide informed consent and follow study instructions~Exclusion Criteria:~* Pigmentary or pseudoexfoliative glaucoma~* Narrow anterior chamber angles or disqualifying corneal thickness in either eye~* Clinically significant ocular disease in either eye~* Previous complicated surgery or certain types of glaucoma surgery in either eye~* Incisional ocular surgery or severe trauma in either eye within the past 6 months~* Uncontrolled systemic disease

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 85 Years
- Healthy Volunteers: f

Study Arms:
- NCX 470 0.021% (Type: EXPERIMENTAL): NCX 470 Ophthalmic Solution, 0.021% dosed once daily for 4 weeks
- NCX 470 0.042% (Type: EXPERIMENTAL): NCX 470 Ophthalmic Solution, 0.042% dosed once daily for 4 weeks
- NCX 470 0.065% (Type: EXPERIMENTAL): NCX 470 Ophthalmic Solution, 0.065% dosed once daily for 4 weeks
- Latanoprost 0.005% (Type: ACTIVE_COMPARATOR): Latanoprost Ophthalmic Solution, 0.005% dosed once daily for 4 weeks

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study of Escalating Doses of Polatuzumab Vedotin in Participants With Relapsed or Refractory B-Cell Non-Hodgkins Lymphoma and Chronic Lymphocytic Leukemia and Polatuzumab Vedotin in Combination With Rituximab in Participants With Relapsed or Refractory B-Cell Non-Hodgkins Lymphoma

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Life expectancy of at least 12 weeks~* History of one of the following histologically-documented hematologic malignancy for which no effective standard therapy exists: indolent non Hodgkin's lymphoma (NHL), Grade 3b follicular lymphoma (FL), diffuse large B-cell lymphoma (DLBCL), mantle cell lymphoma (MCL), or chronic lymphocytic leukemia (CLL)~* All participants (NHL and B-cell chronic lymphocytic leukemia \[B-CLL\]) must have at least one bi-dimensionally measurable lesion~* For all men or women of childbearing potential (unless surgically sterile): use of adequate methods of contraception such as oral contraceptives, intrauterine device, or barrier method of contraception in conjunction with spermicidal jelly~Exclusion Criteria:~* Prior use of any monoclonal antibody or antibody-drug conjugate within 4 weeks before Cycle 1, Day 1~* Treatment with radiotherapy, any chemotherapeutic agent, or treatment with any other investigational anti-cancer agent within 2 weeks prior to Cycle 1, Day 1. Adverse events from any previous treatments must be resolved or stabilized prior to Cycle 1, Day 1, except for neuropathy~* Completion of autologous stem cell transplant within 100 days prior to Cycle 1, Day 1~* Prior allogeneic stem cell transplant

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Polatuzumab Vedotin (Type: EXPERIMENTAL): Polatuzumab vedotin will be administered by an IV infusion of escalating doses (starting dose of 0.1 mg/kg, potentially to be followed by 0.25 mg/kg, 0.5 mg/kg, 1.0 mg/kg, 2.0 mg/kg, and 4.0 mg/kg doses) every 3 weeks (q3w) (Day 1 of each 21 day cycle).
- Polatuzumab Vedotin + Rituximab (Type: EXPERIMENTAL): Polatuzumab vedotin will be administered by an IV infusion q3w (Day 1 of each 21 day cycle). Rituximab was administered by an IV infusion at 375 milligrams per square meter (mg/m\^2) body surface area dose q3w.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete